Optimer Pharmaceuticals, Inc. (OPTR)

[mlkrborn]

Optimer Pharmaceuticals (OPTR) and Tokyo-based Astellas Pharma announced the execution of an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets in Japan for the treatment of Clostridium difficile Infection. In return for the exclusive license to fidaxomicin in Japan, Optimer is entitled to receive a one-time, up-front cash payment of $20 mln from Astellas. Optimer is also eligible to receive additional cash payments of up to $70 mln upon the achievement of certain regulatory and commercial milestones.